UNSPSC 51433300: Antihypertensive phthalazines

Antihypertensive drugs made from benzopyridazines.

UNSPSC 51433300 Antihypertensive phthalazines is a Class code that encompasses emergency medical and prescription medications acquired by state and local health agencies, fire departments, and pharmacy benefit programs—not phthalazine compounds alone, based on actual solicitations. State and local issuers are procuring advanced life support medications (including labetalol, epinephrine, adenosine, and diltiazem) for emergency response, generic multi-source pharmaceuticals through cooperative purchasing alliances serving state and local facilities, and direct-to-manufacturer prescription fulfillment programs through state health commissions. Issuing bodies include city fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). Vendors supply through established drug wholesalers, must meet FDA and cGMP compliance, provide Safety Data Sheets, carry specified insurance coverage, and deliver within strict timeframes, typically with one-year minimum shelf life from manufacture.

Recent activity spans Texas, Minnesota (serving multiple states including Oregon), and Florida. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000, sheltered to Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through AmerisourceBergen (Cencora), Cardinal Health 110 and 112, and Morris & Dickson, with contract effectiveness July 1, 2026, and evaluation weighted heavily to price competitiveness (75 percent). The Texas Health and Human Services Commission issued RFI HHS0017013, with a response deadline of April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, representing preliminary market intelligence before formal RFP issuance.